- Home
- VSTM vs TLSA Comparison
VSTM vs TLSA Comparison
Compare VSTM & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- TLSA
- Stock Information
- Founded
- VSTM 2010
- TLSA 2013
- Country
- VSTM United States
- TLSA United Kingdom
- Employees
- VSTM N/A
- TLSA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- TLSA Health Care
- Exchange
- VSTM Nasdaq
- TLSA Nasdaq
- Market Cap
- VSTM 598.2M
- TLSA 187.0M
- IPO Year
- VSTM 2012
- TLSA 2000
- Fundamental
- Price
- VSTM $9.13
- TLSA $1.67
- Analyst Decision
- VSTM Strong Buy
- TLSA
- Analyst Count
- VSTM 9
- TLSA 0
- Target Price
- VSTM $13.38
- TLSA N/A
- AVG Volume (30 Days)
- VSTM 2.6M
- TLSA 334.2K
- Earning Date
- VSTM 11-05-2025
- TLSA 05-06-2025
- Dividend Yield
- VSTM N/A
- TLSA N/A
- EPS Growth
- VSTM N/A
- TLSA N/A
- EPS
- VSTM N/A
- TLSA N/A
- Revenue
- VSTM $2,137,000.00
- TLSA N/A
- Revenue This Year
- VSTM $88.50
- TLSA N/A
- Revenue Next Year
- VSTM $398.66
- TLSA N/A
- P/E Ratio
- VSTM N/A
- TLSA N/A
- Revenue Growth
- VSTM N/A
- TLSA N/A
- 52 Week Low
- VSTM $2.54
- TLSA $0.63
- 52 Week High
- VSTM $11.25
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- VSTM 53.24
- TLSA 43.49
- Support Level
- VSTM $9.25
- TLSA $1.63
- Resistance Level
- VSTM $10.04
- TLSA $1.88
- Average True Range (ATR)
- VSTM 0.69
- TLSA 0.16
- MACD
- VSTM -0.16
- TLSA -0.01
- Stochastic Oscillator
- VSTM 12.03
- TLSA 32.65
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.